NKTR-262 is under clinical development by Nektar Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect NKTR-262’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 04 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NKTR-262 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

NKTR-262 overview

NKTR-262 is under development for the treatment of solid tumor. It is a small molecule administered through intra tumoral injection. It acts by targeting toll-like receptor (TLR) 7 and toll like receptor 8 (TLR8). It was also under development for ovarian carcinoma, Merkel cell carcinoma and urothelial carcinoma, relapsed/refractory metastatic melanoma, Merkel cell carcinoma (MCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), colorectal cancer, head and neck squamous cell carcinoma (HNSCC) and sarcoma

Nektar Therapeutics overview

Nektar Therapeutics (Nektar) discovers and develops novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. The company’s technology platforms offer a wide range of functional attributes, which optimizes and enhances the profile of a wide range of molecules including large classes of drugs targeting numerous disease areas. The company’s products focus on various disease areas including cancer, pain, infections, and immunology, among others. Its research and development involve peptides, proteins, antibodies, small molecule drugs, and other potential biological drug candidates. Nektar Therapeutics is headquartered in San Francisco, California, the US.

Quick View NKTR-262 LOA Data

Report Segments
  • Innovator
Drug Name
  • NKTR-262
Administration Pathway
  • Intratumor
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.